Angiotensin II receptor type 1

Angiotensin II receptor type 1
Name	Angiotensin II receptor type 1
Uniprot	P30556
Location	3q24
Family	G protein-coupled receptor (GPCR)

Angiotensin II receptor type 1 is a G protein-coupled receptor that binds the octapeptide hormone angiotensin II and mediates vasoconstrictive, pro-inflammatory, and pro-fibrotic effects. It is central to regulation of blood pressure and fluid balance and is a major target for clinical antihypertensive therapy. The receptor's role has been characterized across molecular, physiological, and clinical research involving cardiovascular, renal, and endocrine systems.

Structure and molecular characteristics

Angiotensin II receptor type 1 is a seven-transmembrane helix GPCR encoded by the AGTR1 gene on human chromosome 3 and exhibits the canonical GPCR topology described in structural studies of rhodopsin, beta-adrenergic receptors, and muscarinic receptors. Crystallographic and cryo-EM analyses of related class A GPCRs such as the Rhodopsin and Beta-2 adrenergic receptor families have informed models of ligand binding and activation for AGTR1, implicating conserved motifs (DRY, NPxxY) and microswitch networks. The receptor interacts with heterotrimeric G proteins (notably Gq/11) and beta-arrestins, similar to mechanisms elucidated for G protein-coupled receptor kinase 2 and Beta-arrestin 2 in studies involving Nobel Prize in Chemistry–recognized GPCR research. Post-translational modifications including N-linked glycosylation, palmitoylation, and phosphorylation by kinases such as Protein kinase A and G protein-coupled receptor kinase 5 modulate receptor trafficking and desensitization. The AGTR1 protein shares structural and pharmacophoric features with other peptide-recognizing receptors characterized by groups working at institutions like Harvard University, Max Planck Society, and Cold Spring Harbor Laboratory.

Function and signaling pathways

Activation of angiotensin II receptor type 1 by angiotensin II triggers Gq/11-mediated phospholipase C activation, inositol trisphosphate generation, calcium mobilization, and protein kinase C activation—pathways also central to signaling through receptors studied at Stanford University, University of Oxford, and Massachusetts Institute of Technology. Downstream effectors include mitogen-activated protein kinases (MAPKs) such as ERK1/2, p38, and JNK, with cross-talk to receptor tyrosine kinase pathways exemplified by transactivation of the Epidermal growth factor receptor and pathways explored in labs at Johns Hopkins University and University of California, San Francisco. Beta-arrestin–dependent signaling produces distinct transcriptional responses and internalization dynamics, a concept advanced in research involving Howard Hughes Medical Institute investigators and collaborators at Columbia University. AGTR1 signaling integrates with oxidant-generating systems including NADPH oxidases characterized by work at Yale University and University of Cambridge, contributing to redox-sensitive gene regulation.

Physiological roles and distribution

Angiotensin II receptor type 1 is abundantly expressed in vascular smooth muscle, adrenal cortex, kidney (particularly efferent arteriole and proximal tubule), heart, brain regions including the hypothalamus and brainstem, and in immune cells; these distributions mirror physiological roles described in comparative anatomy and physiology studies from institutions such as Karolinska Institutet, University of Tokyo, and University of Toronto. Through effects on vasoconstriction, aldosterone secretion by the Zona glomerulosa, sodium reabsorption in renal tubules, and sympathetic activation mediated via nuclei studied at King's College London, AGTR1 contributes to long-term control of arterial pressure and extracellular fluid volume. In the central nervous system, AGTR1 influences thirst and antidiuretic hormone release coordinated by pathways involving the Supraoptic nucleus and Paraventricular nucleus as documented in neuroendocrinology literature from Uppsala University and National Institutes of Health. Roles in cell growth, hypertrophy, and fibrosis link AGTR1 to tissue remodeling processes highlighted in research from Mayo Clinic and Cleveland Clinic.

Pathophysiology and clinical implications

Dysregulated angiotensin II receptor type 1 signaling contributes to hypertension, heart failure, chronic kidney disease, atherosclerosis, and vascular inflammation—conditions extensively investigated in clinical centers such as Cleveland Clinic Foundation, Mount Sinai Hospital, and Mayo Clinic Hospital. AGTR1-mediated oxidative stress and inflammatory gene programs promote endothelial dysfunction and plaque progression linked to major cardiovascular outcome studies conducted by consortia including European Society of Cardiology and American Heart Association. In heart failure, AGTR1-driven remodeling underlies maladaptive hypertrophy and fibrosis characterized in trials at Johns Hopkins Hospital and Brigham and Women's Hospital. AGTR1 also has roles in metabolic disease and insulin resistance noted in epidemiological cohorts like those managed by Framingham Heart Study investigators and public health research at Centers for Disease Control and Prevention. Autoimmune and renal disorders show AGTR1-associated pathways implicated in biopsy and molecular profiling studies from Karolinska University Hospital and Guy's and St Thomas' NHS Foundation Trust.

Pharmacology and therapeutic targeting

AGTR1 is the pharmacological target of angiotensin receptor blockers (ARBs) such as losartan, valsartan, irbesartan, candesartan, olmesartan, and telmisartan, therapies validated in randomized controlled trials led by groups at University College London, Imperial College London, Harvard Medical School, and Stanford School of Medicine. ARBs reduce blood pressure, lower proteinuria in nephropathy, and improve outcomes in heart failure, as shown in multicenter trials overseen by organizations including World Health Organization and National Institute for Health and Care Excellence. Pharmacodynamics include competitive antagonism at the orthosteric angiotensin II binding site and inverse agonism in some compounds, while newer biased ligands and allosteric modulators aim to preferentially engage beta-arrestin pathways—approaches developed in medicinal chemistry programs at Pfizer, AstraZeneca, Novartis, and academic labs at University of Cambridge. Drug interaction and safety profiles have been defined through postmarketing surveillance coordinated with agencies like Food and Drug Administration and European Medicines Agency.

Genetic variation and regulation

Polymorphisms in AGTR1, including the A1166C variant and promoter region changes, have been studied for associations with hypertension, stroke, and cardiovascular risk in population cohorts such as the Framingham Heart Study, UK Biobank, and EPIC project. Gene expression of AGTR1 is regulated by transcription factors and epigenetic mechanisms investigated in genetics centers at Broad Institute, Wellcome Sanger Institute, and Cold Spring Harbor Laboratory. Rare mutations and altered AGTR1 signaling are evaluated in familial and precision medicine contexts at institutions like Mayo Clinic and National Institutes of Health Clinical Center. Copy number variation, microRNA targeting, and alternative splicing add regulatory complexity with implications for personalized therapy strategies pursued in translational programs at Massachusetts General Hospital and Dana-Farber Cancer Institute.

Category:G protein-coupled receptors